11. Pereira D, Peleteiro B, Araújo J, Branco J, Santos RA, Ramos E: The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage. 2011; 19: 1270–1285

12. Zhou ZY, Liu YK, Chen HL, Liu F: Body mass index and knee osteoarthritis risk: a dose-response meta-analysis. Obesity (Silver Spring). 2014; 22: 2180–2185

13. Altman RD: Early management of osteoarthritis. Am J Manag Care. 2010; 16 Suppl Management: S41–S47

14. Salaffi F, Carotti M, Stancati A, Grassi W: Health-related quality of life in older adults with symptomatic hip and knee osteoarthritis: a comparison with matched healthy controls. Aging Clin Exp Res. 2005; 17: 255–263

15. Kauppila AM, Kyllonen E, Mikkonen P et al.: Disability in end-stage knee osteoarthritis. Disabil Rehabil. 2009; 31: 370–380

16. Dawson J, Linsell L, Zondervan K et al.: Epidemiology of hip and knee pain and its impact on overall health status in older adults. Rheumatology (Oxford). 2004; 43: 497–504

17. Cheraghi-Sohi S, Bower P, Kennedy A, et al. Patient priorities in osteoarthritis and comorbid conditions: a secondary analysis of qualitative data. Arthritis Care Res (Hoboken). 2013; 65: 920–927

18. Bogardus ST Jr, Holmboe E, Jekel JF: Perils, pitfalls, and possibilities in talking about medical risk. JAMA. 1999; 281: 1037–1041

19. Hulka BS, Wheat JR: Patterns of utilization. The patient perspective. Med Care. 1985; 23: 438–460

20. Cher DJ, Miyamoto J, Lenert LA : Incorporating risk attitude into Markov-process decision models: importance for individual decision making. Med Decis Making. 1997; 17: 340–350

21. Ali A, Sundberg M, Robertsson O et al.: Dissatisfied patients after total knee arthroplasty: a registry study involving 114 patients with 8–13 years of followup. Acta Orthop. 2014; 85: 229–233

22. Chuck A, Adamowicz W, Jacobs P, Ohinmaa A, Dick B, Rashiq S: The willingness to pay for reducing pain and pain-related disability. Value Health. 2009; 12: 498–506

23. Fraenkel L, Suter L, Cunningham CE, Hawker G: Understanding preferences for disease-modifying drugs in osteoarthritis. Arthritis Care Res (Hoboken). 2014; 66: 1186–1192

24. Barlow JH, Turner AP, Wright CC: Comparison of clinical and self-reported diagnoses for participants on a community-based arthritis self-management programme. Br J Rheumatol. 1998; 37: 985–987

25. Rasooly I, Papageorgiou AC, Badley EM: Comparison of clinical and self reported diagnosis for rheumatology outpatients. Ann Rheum Dis. 1995; 54: 850–852

26. Breivik H, Borchgrevink PC, Allen SM, et al.: Assessment of pain. Br J Anaesth. 2008; 101: 17–24

27. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP: Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983; 26: 1346–1353

28. Vignon E, Valat JP, Rossignol M et al.: Osteoarthritis of the knee and hip and activity: a systematic international review and synthesis (OASIS). Joint Bone Spine. 2006; 73: 442–455

29. Hauber AB, Arden NK, Mohamed AF, et al. A discrete-choice experiment of United Kingdom patients’ willingness to risk adverse events for improved function and pain control in osteoarthritis. Osteoarthritis Cartilage. 2013;21:289–297.

30. Wang Y, Hall S, Hanna F et al. Effects of Hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. BMC Musculoskelet Disord. 2011; 12: 195

31. Pal S, Thuppal S, Reddy KJ et al.: Long-term (1-year) safety and efficacy of a single 6-mL injection of Hylan G-F 20 in Indian patients with symptomatic knee osteoarthritis. Open Rheumatol J. 2014; 8: 54–68

32. Balmaceda CM. Clinical trial data in support of changing guidelines in osteoarthritis treatment. J Pain Res. 2014; 7: 211–218

Fussnoten

* Dieser Artikel wurde in der folgenden Dove-Press-Fachzeitschrift publiziert: Patient Preference and Adherence. 11. Juni 2015

1 Heron Commercialization, Parexel International, London (GB)

2 Reason Research, Philadelphia, PA (USA)

3 Sanofi Biosurgery, Oxford (GB)

4 Sanofi, Paris (Frankreich)